Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.
Francesco Sparano, MSc
Advertisement
Francesco Sparano, MSc, is a research associate in the health outcomes research unit at the Italian-based GIMEMA Foundation.
Articles by Francesco Sparano, MSc
Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5
